Health Economics and Decision Science, University of Sheffield, Sheffield, England, UK.
Acaster Lloyd Consulting Ltd, London, England, UK.
Value Health. 2020 Mar;23(3):397-405. doi: 10.1016/j.jval.2019.12.004. Epub 2020 Feb 15.
The aims of this study were to examine current reporting standards of health state utilities (HSU) using a review of published cost-effectiveness analyses in cardiovascular disease and to explore the impact of variation in model inputs used in these on estimated quality-adjusted life-years (QALYs) and cost-effectiveness.
Key health/economics bibliographic databases were searched to identify relevant articles published after 2014. Any narrative or values relating to the HSU used in the model were extracted and reviewed. The HSUs were systematically applied to an existing model to explore the influence of different values on QALYs and the incremental cost-effectiveness ratio.
Twenty-four peer-reviewed articles were identified. Only 2 studies referred to a literature review for the HSUs. Most (18 of 24) referenced previously published economic studies (as opposed to the original source) for at least 1 of the HSUs. Only 4 studies referenced the original sources and reported all of the HSUs accurately, and several did not provide all the HSUs. Little information was provided on the methods used to calculate QALYs, for example, the duration of time for acute HSUs, what the baseline HSU was, the method that was used to assign HSUs for subsequent different events, or how constant HSUs for clinical events were combined with age-adjusted baseline values. The huge differences in HSUs used in the studies produced substantial variations in the QALYs and incremental cost-effectiveness ratios generated from the cost-effectiveness model.
Current standards are poor, and there is a need for greater transparency in reporting the HSUs used in cost-effectiveness models.
本研究旨在通过对已发表的心血管疾病成本效益分析进行综述,考察健康状态效用(HSU)的当前报告标准,并探讨这些模型中使用的不同模型输入对估计质量调整生命年(QALYs)和成本效益的影响。
检索了主要的健康/经济文献数据库,以确定 2014 年后发表的相关文章。提取并审查了模型中使用的任何与 HSU 相关的叙述或价值。系统地将 HSU 应用于现有模型,以探讨不同值对 QALYs 和增量成本效益比的影响。
确定了 24 篇同行评审文章。只有 2 项研究提到了 HSU 的文献综述。大多数(24 篇中的 18 篇)至少引用了 1 项先前发表的经济研究(而不是原始来源)作为 HSU 的来源。只有 4 项研究参考了原始来源并准确报告了所有 HSU,并且有几项没有提供所有 HSU。关于计算 QALYs 使用的方法提供的信息很少,例如,急性 HSU 的持续时间,基础 HSU 是什么,用于为随后的不同事件分配 HSU 的方法,或者如何将临床事件的恒定 HSU 与年龄调整后的基线值相结合。研究中使用的 HSU 存在巨大差异,导致成本效益模型生成的 QALYs 和增量成本效益比产生了很大变化。
目前的标准较差,需要在报告成本效益模型中使用的 HSU 方面提高透明度。